Short answer
Anteris Technologies Global Corp. (AVR) filed its Q3 2025 10-Q quarterly report on Nov 12, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $429,000 with net income of −$22M.
Q3 2025 key financials · XBRL
- Revenue
- $429,000
- −30.6% QoQ
- Net income
- −$22M
- −6.8% QoQ
- Operating margin
- -5190.0%
- EPS (diluted)
- −$0.62
- −8.8% QoQ
Source: XBRL data from the Anteris Technologies Global Corp. (AVR) Q3 2025 10-Q on SEC EDGAR. USD.
Anteris Technologies Global Corp. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $0.4M vs $0.8M, down 44% YoY, following LeMaitre agreement expiration
- Q3 operating loss $22.3M vs $20.6M; operating margin -5,190.0% vs -2,677.5% YoY
- R&D expense $16.8M, up 21%; SG&A $5.8M, down 17%
- Cash, equivalents and restricted cash $9.1M vs $70.5M at December 31, 2024
- Operating cash outflow $59.3M vs $43.0M; private placement generated approximately $25.2M gross proceeds after quarter-end
Risk Factors
- PARADIGM Trial success remains uncertain despite FDA IDE approval
- FDA may revoke IDE approval or deny PMA for DurAVR THV System
- Post-market testing or controls could impose additional FDA compliance costs
- Regulatory scrutiny could discourage physician use and damage product reputation
- $52.7 million allocated to DurAVR development and PARADIGM Trial preparation and enrollment
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Anteris Technologies Global Corp. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.